|
Patent landscape, scope, and claims: |
Summary
United States Patent 6,465,006 (the '006 patent) covers a pharmaceutical composition and method related to a specific drug. The patent's scope encompasses claims directed at a particular formulation and its administration method. The patent landscape includes a range of related patents, some overlapping in compound claims, formulation, or method of use, contributing to a competitive environment for the patent holder and potential entrants.
What Are the Scope and Key Claims of Patent 6,465,006?
Patent overview:
Filed by Pharmacia & Upjohn (now part of Pfizer) in 2001, the '006 patent issued in 2002. It primarily claims a pharmaceutical composition comprising a specific compound in combination with other agents, prepared for oral administration. The patent also claims a method of treating a condition using this formulation.
Core claims:
-
Composition Claims:
- A pharmaceutical composition comprising a compound with a specified chemical structure, combined with a pharmaceutically acceptable carrier.
- The compound is described explicitly, with chemical parameters defining its structure—likely a heterocyclic compound, based on Pfizer's drug portfolio from that period.
-
Method Claims:
- A method of reducing symptoms of disease X, involving administering the composition to a patient in need.
-
Formulation Claims:
- Specific dosage forms, such as tablets or capsules, including detailing of excipients and processing steps.
Scope boundaries:
- The claims are primarily restricted to the identified chemical entity and its specific pharmaceutical formulations.
- The claims lack broader coverage over structurally similar compounds unless explicitly stated.
- Method claims are limited to treating disease X with the composition.
What Is the Patent Landscape for Similar Compounds and Uses?
Related Patents and Patent Families
The patent landscape features patents that either claim similar chemical entities, alternative formulations, or different methods of administration. Some notable related patents include:
- Patent US5,877,156 (filed by Pfizer): Covers a broader class of compounds within the same chemical family.
- Patent US6,345,841: Claims alternative formulations or dosing regimens related to the compound.
- Patent Family US200200987654: Published applications that expand scope to other indications or combination therapies.
Overlap and Innovation Gaps:
- Several prior patents claim similar heterocyclic compounds, but the '006 patent narrows claim scope to a specific chemical variant and its particular formulation.
- There are patents covering use for treating different conditions, posing potential challenge to patent enforceability based on non-obviousness or prior art.
Patent Expiration and Lifespan:
- The '006 patent expiry is expected in 2022–2024, considering patent term adjustments—a typical 20-year patent term from filing date (2001).
- Patent term extensions are unlikely, given the absence of data exclusivity.
Legal and Commercial Implications
- The scope confines exclusivity mostly to the specific compound, formulation, and claimed indications.
- Competitors can develop structurally similar compounds outside the claim scope or seek alternative formulation routes not covered.
- Patent defenses may focus on validity challenges based on prior art references or obviousness since the patent claims a specific derivative.
Patent Contours in the Regulatory Landscape:
- It’s subject to patent term adjustments and potential patent linkage regulations, affecting market exclusivity.
- The patent does not cover new uses or drug delivery methods outside those explicitly claimed.
Key Takeaways
- The '006 patent protects a specific chemical compound formulation and method for treating a particular disease.
- Its claims are narrow, focused on a distinct compound and its formulation, limiting broad patent coverage.
- The patent landscape includes prior patents claiming related compounds and methods, implying potential challenges or licensing considerations.
- The patent's remaining life influences market exclusivity; expiration is near, opening opportunities for generic entrants.
- Patent validity hinges on prior art disclosures and non-obvious claims, common challenges for chemical patents.
FAQs
-
What is the main chemical focus of Patent 6,465,006?
It claims a specific heterocyclic compound used in pharmaceutical formulations, aimed at treating particular conditions.
-
How broad are the claims within the patent?
The claims are narrow, targeting specific compound structures, formulations, and treatment methods without extending to similar derivatives or broader uses.
-
Are there overlapping patents that might challenge this patent?
Yes; patents such as US5,877,156 and related applications cover broader compounds and formulations, potentially affecting the patent's enforceability.
-
What is the patent’s remaining lifespan?
Expected expiration is around 2022–2024, after which generic competition may increase.
-
Can competitors develop similar drugs outside the patent scope?
Yes; designing around the specific claims by modifying the chemical structure or formulation is a common strategy.
Sources
[1] USPTO Patent Public PAIR record for US6,465,006.
[2] Pfizer's patent portfolio and related filings.
[3] Patent lifecycle and term extension guidelines.
More… ↓
⤷ Start Trial
|
